Jan 12 (Reuters) - The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.


40


Reuters

Latest News

USA Today: Kang finishes strong to win LPGA Shanghai by 2 strokes

USA Today: Kang finishes strong to win LPGA Shanghai by 2 strokes

Daily Mail: Today show weather presenter Natalia Cooper recalls meeting her hubby Carl Fox at a pub in Perth

Daily Mail: Merrick demands better from VAR officials

Daily Mail: Hawks overcome Cairns NBL hoodoo

Daily Mail: Officials play 'war games' on how they might call and run a second referendum on Brexit

FOX: Trump rallies in Clinton-won districts ahead of midterms

Daily Mail: US Mega Millions jackpot hits 1.6bn dollars

Daily Mail: Pregnant Meghan takes break from Australia royal tour

Daily Mail: Agatha Christie's taste for poison was inspired by her experiences as a wartime nurse

Daily Mail: King Henry VIII was a 'vulnerable, insecure and loyal' king, says expert

Reuters: China says must balance stable growth and risk prevention

Haaretz: A timeline of Saudi Arabia's shifting narratives on Jamal Khashoggi's death

NewYorkTimes: ‘The Miseducation of Lauryn Hill’ Kids, 20 Years Later

Daily Mail: Bank of England remains under fire over `staggeringly´...

Daily Mail: Next Bank of England chief does not need to be a woman,...

Daily Mail: Man slashed on the face, back, shoulders and arms by friend armed with a box cutter in Potts Point

Daily Mail: Kang finishes strong to win LPGA Shanghai by 2 strokes

Reuters: Iran's Rouhani appoints new economy minister in reshuffle

Jpost: Russia: U.S. withdrawal from nuclear treaty is a dangerous step

FOX: VIDEO: Police officers help free deer caught in fence

BBC: Scotland's papers: Plans for first film studio

ABC: 5 major issues dominating the midterm elections: ANALYSIS